IFM Phase II Study: KRd Induction and Consolidation Before Len Maintenance Highly Effective in Newly Diagnosed MM

December 3-6, 2016; San Diego, California
KRd for 8 cycles of induction and consolidation therapy in patients with MM was highly effective but resulted in some cardiovascular adverse events.
Format: Microsoft PowerPoint (.ppt)
File Size: 552 KB
Released: December 9, 2016

Acknowledgements

This activity is supported by educational grants from
Amgen
Celgene Corporation
Incyte
Merck & Co., Inc.
Seattle Genetics

Related Content

Read expert answers to clinician questions on optimizing the care of patients with CLL in today’s practice, from Clinical Care Options (CCO)

Ian W. Flinn, MD, PhD Susan M. O'Brien, MD John Pagel Headshot John Pagel, MD, PhD Released: January 15, 2021

Expert answers to clinician questions on current challenges in managing patients with myelodysplastic syndromes (MDS), from Clinical Care Options (CCO)

Guillermo Garcia-Manero, MD Rami S. Komrokji, MD Jamile Shammo, MD, FASCP, FACP Released: January 11, 2021

Expert commentary by Lydia Scarfò, MD, providing a European perspective on key studies in CLL and lymphomas from ASH 2020 as reported by Clinical Care Options (CCO)

Lydia Scarfò, MD Released: January 4, 2021

Gain key clinical insights fast, with this short slideset from CCO on optimal management of patients with MM

Brian G.M. Durie, MD Shaji Kumar, MD Thomas G. Martin, MD Philippe Moreau, MD S. Vincent Rajkumar, MD Jesús F. San-Miguel, MD, PhD Released: December 30, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue